Hypersensitivity to isavuconazole may result in anaphylactic reaction, hypotension, resp failure, dyspnoea, drug eruption, pruritus & rash; other azole antifungals. Discontinue use if severe cutaneous AR (eg, SJS) develops. Patients concomitantly taking other medicinal products known to decrease QT interval (eg, rufinamide). Consider monitoring of hepatic enzymes. Risk of hepatitis. Concomitant use w/ CYP3A4/5 inhibitors (eg, ketoconazole, lopinavir/ritonavir), inducers (eg, aprepitant, prednisone, pioglitazone) & substrates including immunosuppressants (eg, tacrolimus, sirolimus, ciclosporin); CYP2B6 substrates (eg, cyclophosphamide); P-gp substrates (eg, digoxin, colchicine, dabigatran etexilate). No dose-finding study in mucormycosis; patients were administered w/ same dose as used for invasive aspergillosis. Avoid driving or operating machinery if symptoms of confusional state, somnolence, syncope &/or dizziness are experienced. Carefully monitor for potential drug toxicity in patients w/ severe hepatic impairment (Child-Pugh Class C). Not recommended for women of childbearing potential not using contraception. Pregnancy. Discontinue breast-feeding during treatment. Childn <18 yr. Elderly. IV: Discontinue use if infusion-related reactions including hypotension, dyspnoea, dizziness, paraesthesia, nausea & headache occur.
Sign Out
